Understanding the Role of Targets and Pathways in the Treatment of Melanoma
This CME/CE/CPE certified supplement is jointly provided by:
Editorial
A Letter From the Guest Editors
Lisa A. Kottschade, APRN, MSN, CNP, and LeAnn B. Norris, PharmD, FCCP, BCPS, BCOP
Read MoreEditorial
A Brighter Future for Patients With Melanoma
Lisa A. Kottschade, APRN, MSN, CNP, and LeAnn B. Norris, PharmD, FCCP, BCPS, BCOPRead MoreReview Article
Diagnosis, Evaluation, and Surgical Management of Melanoma
Brianna Hoffner, MSN, ANP-BC, AOCNP®, and Christan G. Bartsch, MSHS, PA-C, MPHRead MoreReview Article
Harnessing the Immune System in the Treatment of Melanoma
Suzanne McGettigan, MSN, CRNP, AOCN®Read MoreReview Article
BRAF/MEK Inhibition in Melanoma: An Update
Lisa A. Kottschade, APRN, MSN, CNP, and Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP®, APHNRead MoreReview Article
Mutations Beyond BRAF V600
Mollie Reed, MSN, ACNP-BCRead MoreReview Article
Melanomas of Noncutaneous Origin: Diagnosis, Treatment, and Outcomes
Lisa A. Kottschade, APRN, MSN, CNPRead MoreReview Article
Supportive Care and Management of Treatment-Related Adverse Effects From Immune Checkpoint Inhibitors and Targeted Therapies in Melanoma
Krista M. Rubin, MS, FNP-BC, and Lisa A. Kottschade, APRN, MSN, CNPRead MoreReview Article
Drug-Drug Interactions in Melanoma
LeAnn B. Norris, PharmD, FCCP, BCPS, BCOPRead MoreAppendix
Appendix
Compiled by Lisa A. Kottschade, APRN, MSN, CNPRead More